Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbisko CaymanHKSE:02256 -2.95%56 EV-to-FCF is 70.25 as of Aug. 15, 2026, which is 659% above its 10-year median of 9.25. GuruFocus rates HKSE:02256 with a GF Score™ of 56/100 and a GF Value™ of HK$12.30 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 332 Biotechnology companies, Abbisko Cayman ranks worse than 81.33% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Abbisko Cayman's Enterprise Value is HK$5,477.1 Mil.
Abbisko Cayman's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$78.0 Mil. Therefore, Abbisko Cayman's EV-to-FCF for today is 70.25.
The historical rank and industry rank for Abbisko Cayman's EV-to-FCF or its related term are showing as below:
HKSE:02256'
s EV-to-FCF Range Over the Past 10 Years
Min: -449.99 Med: 9.25 Max: 89.5
Current: 70.25
During the past 7 years, the highest EV-to-FCF of Abbisko Cayman was 89.50. The lowest was -449.99. And the median was 9.25.
HKSE:02256's EV-to-FCF is ranked worse than 81.33% of 332
companies
in the Biotechnology industry
Industry Median: 16.745
vs HKSE:02256: 70.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abbisko Cayman's PE Ratio (TTM) for today is calculated as:
Abbisko Cayman's share price for today is HK$10.54.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.071.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Abbisko Cayman EV-to-FCF Related Terms
Abbisko Cayman EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Abbisko Cayman's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02256 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Abbisko Cayman's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's EV-to-FCF falls into.
Abbisko Cayman's current Enterprise Value is HK$5,477.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$78.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (HKSE:02256) has a EV-to-FCF of 70.25 as of Aug. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abbisko Cayman and its competitors. This is 659% above median its historical median of 9.25. According to the industry distribution chart, Abbisko Cayman ranks #270 out of 332 companies in the Biotechnology industry, placing it in the top 81.3%.
Is Abbisko Cayman's EV-to-FCF too high?
Abbisko Cayman's current EV-to-FCF of 70.25 is 659% above median its 10-year median of 9.25. The Biotechnology industry median EV-to-FCF is 16.75. Abbisko Cayman's value of 70.25 is 319.5% above this industry median. Based on the distribution chart, Abbisko Cayman ranks #270 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abbisko Cayman has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #270 out of 332 companies for EV-to-FCF. This places Abbisko Cayman in the lower half of its industry. The industry median EV-to-FCF is 16.75. Abbisko Cayman's value of 70.25 is 319.5% above this benchmark. While the company's 10-year median is 9.25 vs. the industry median of 16.75, Abbisko Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.75, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbisko Cayman's current EV-to-FCF of 70.25 is 319.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abbisko Cayman and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbisko Cayman's current EV-to-FCF is 70.25, which is 659% above median its own 10-year median of 9.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (HKSE:02256) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$12.30, compared to a current price of HK$10.54 — trading 14.3% below its estimated fair value. The current EV-to-FCF is 70.25, which is 659% above median its 10-year median of 9.25 and 319.5% above the Biotechnology industry median of 16.75. Abbisko Cayman's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Abbisko Cayman (HKSE:02256), the current EV-to-FCF is 70.25 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30.
GuruFocus considers Abbisko Cayman to be Modestly Undervalued.
Key valuation signals for HKSE:02256:
EV-to-FCF: 70.25 (659% above median its 10-year median of 9.25)
GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
Industry Position: 319.5% above the Biotechnology median (#270 of 332)
No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score
Get the complete analysis for HKSE:02256
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02256 has been successfully added to your 
